Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

• Published in: Lupus science & medicine Vol. 8; no. 1; p. e000464
• Main Authors: Tummala, Raj, Abreu, Gabriel, Pineda, Lilia, Michaels, M Alex, Kalyani, Rubana N, Furie, Richard A, Morand, Eric F
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 17.02.2021; BMJ Publishing Group
• Series: Original research
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Clinical medicine; Clinical Trials and Drug Discovery; Gene expression; Heart attacks; Humans; Hypertension; Immunosuppressive agents; Infections; Lupus Erythematosus, Systemic - drug therapy; Monoclonal antibodies; Mortality; Patients; Population; Respiratory Tract Infections; Statistical analysis; systemic; therapeutics; lupus erythematosus; interferon type I; outcome assessment; health care; biological products

ObjectiveIn phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using data pooled from these trials to more precisely estim...